Earnings per share (EPS) is the portion of a company's profit allocated to each outstanding share of common stock. On average, analysts expect that Abbott Laboratories will post $2.47 earnings per share for the current year.
Abbott Laboratories (NYSE:ABT) shares were trading higher by 0.15 percent ($0.08) at $55 a piece in Friday's session. Abbott Laboratories (NYSE:ABT) has risen 15.90% since October 9, 2016 and is uptrending. It has underperformed by 16.70% the S&P500.
Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The firm has a market capitalization of $95.56 billion, a P/E ratio of 77.03 and a beta of 1.06. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products.
Abbott Laboratories (NYSE:ABT) was up +0.15% ($0.08) to $55 and showed a volume of 4.19 mln shares. Therefore 58% are positive. The lowest target is $186.0 while the high is $240.0. The stock closing price is now trading upward to its 50 day moving average with change of 8.22%, escalated to its 20 day moving average with figure of 4.48% and above its 200 day moving average with value 19.35%. Pnc Finance Svcs Group holds 0.38% of its portfolio in Abbott Laboratories (NYSE:ABT) for 7.27 million shares. The firm has "Market Perform" rating given on Wednesday, August 5 by BMO Capital Markets. 9 of them rate its stock a hold. Kidder Stephen W holds 2.53% in Abbott Laboratories (NYSE:ABT) or 137,509 shares.
Analysts have given a mean recommendation of 2.00 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). As per Thursday, August 4, the company rating was maintained by Jefferies. The rating was upgraded by Edward Jones to "Buy" on Tuesday, June 21. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. July 21 investment analysts at Deutsche Bank held the company rating at "Buy" but raised the price target to $56.00 from $54.00. Investors of record on Friday, April 14th were issued a dividend of $0.265 per share. The dividend will be $0.265 per share for the quarter which comes to $1.06 on an annualized basis. The ratio is negative, as 543 investment managers started new and increased holdings, while 614 reduced and sold equity positions in Abbott Laboratories. 35 funds opened positions while 119 raised stakes. Perella Weinberg Prtn Mgmt Lp holds 0.36% of its portfolio in Abbott Laboratories (NYSE:ABT) for 60,914 shares. Canada Pension Plan Investment Board reported 2.71 million shares stake. Reliance Of Delaware reported 0.14% in Abbott Laboratories (NYSE:ABT). During the same period in the previous year, the business posted $0.55 earnings per share. Allen Investment Mngmt Limited Liability reported 0.03% in Abbott Laboratories (NYSE:ABT). The legal version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/08/bbva-compass-bancshares-inc-has-11-25-million-stake-in-abbott-laboratories-abt.html. Plante Moran Fincl Lc, a Michigan-based fund reported 12,019 shares. Zevin Asset Mgmt Limited Liability invested in 6,753 shares.
08/17/2017 - Citigroup began new coverage on Abbott Laboratories giving the company a "neutral" rating. The Florida-based Independent Port Consultants Incorporated has invested 0.04% in Abbott Laboratories (NYSE:ABT). Investors will be watching the company shares closely as we head through earnings season.
Gruss & Co Inc decreased W P Carey Inc (WPC) stake by 38.77% reported in 2017Q2 SEC filing. Southeastern Asset Management Inc Tn owns 4.71 million shares or 11.25% of their United States portfolio.
Since June 15, 2017, it had 0 buys, and 1 insider sale for $26,482 activity.
Among 24 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 10 Hold. The high and low revenue estimates for the current quarter are $7.28 Billion and $6.7 Billion, respectively. The stock was sold at an average price of $50.00, for a total transaction of $750,000.00.
AntaresPharma, Inc. (ATRS) stock moved with shift of 20.06% in the past week.
07/10/2017 - Abbott Laboratories had its "equal-weight" rating reiterated by analysts at Morgan Stanley. The company was maintained on Thursday, September 28 by Wells Fargo. The company was downgraded on Friday, November 13 by Goldman Sachs. Lake Street initiated it with "Buy" rating and $18 target in Monday, September 19 report.
Receive Abbott Laboratories News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories with MarketBeat.com's FREE daily email newsletter.
- Huawei Quietly Launches Android Oreo Beta Program For Mate 9
- President Trump rips ESPN ratings, Jemele Hill
- Stock within Investors Radar: Anadarko Petroleum Corporation (APC)
- Microsoft Inks a Deal for Wind Power from GE in Ireland
- Martin O'Neill proud of "magnificent" Republic of Ireland
- Sensex, Nifty remain firm
- Jio Payments Bank reportedly launching in December this year
- Trump suggests cutting NFL's 'massive tax breaks' because of players' anthem protests
- Girls' Generation in crisis
- Warm, cloudy with one or two showers today